Genetic counseling

Gundersen Health System Expands Genetics Program with Genome Medical's Telegenetic Counseling Services

Retrieved on: 
Thursday, June 22, 2023
Partnership, Gundersen Health System, Pediatrics, Cancer, Gundersen, National Comprehensive Cancer Network, NCCN, Organization, Genetic counseling, Journal of the National Comprehensive Cancer Network, Patient, Edge, SAN, WI, Genetic testing, RN, Growth, Cardiology, Health, Neurology, Pharmaceutical industry, Vaccine, Nursing

SOUTH SAN FRANCISCO, Calif., June 22, 2023 /PRNewswire/ -- Gundersen Health System, a physician-led, non-profit, comprehensive integrated healthcare network, Edge, Gundersen's Innovation arm, and Genome Medical, the leading telehealth provider of genetic services and genomics-based care, are teaming up to expand Gundersen's genetic and preventive care services for patients with cancer and their families.

Key Points: 
  • Gundersen partnership with Genome Medical will reduce wait times from approximately 10 months to less than 7 days.
  • "Gundersen Health System has an outstanding track record for the patient care and experience it provides across its communities.
  • We are excited to be a partner in their growth by augmenting their genetics program with Genome Medical's services," says Jill Davies, CEO, Genome Medical.
  • Genome Medical genetic counselors, medical geneticists and other specialists provide virtual genetics services across every major area of clinical care, including oncology, cardiology, rare disease, neurology, reproductive health and pediatrics.

Dante Genomics offers new Rare Disease Health Package to help bring diagnoses to the millions of people living with rare diseases and ending what can be years-long diagnostic odysseys

Retrieved on: 
Monday, June 5, 2023
Genomics, Prognosis, Privacy, Whole genome sequencing, Genetic counseling, Patient, HIPAA, Medicine, WGS, Genetic testing, GDPR, Diagnosis, Rare, Rare disease

NEW YORK, June 5, 2023 /PRNewswire/ -- Dante Genomics, a global leader in genomics and precision medicine, today announced the launch of its Rare Disease Health Package to revolutionize rare disease diagnosis with whole genome sequencing testing.

Key Points: 
  • NEW YORK, June 5, 2023 /PRNewswire/ -- Dante Genomics , a global leader in genomics and precision medicine, today announced the launch of its Rare Disease Health Package to revolutionize rare disease diagnosis with whole genome sequencing testing.
  • The Rare Disease Health Package includes pre- and post-telemedicine consultations with specialist doctors, providing access to specialists who may not be available in a patient's area.
  • Dante removes financial barriers to care by identifying potential treatments and management strategies for rare diseases.
  • With rare diseases in particular, early diagnosis is crucial for optimal treatment, care and genetic counseling regarding prognosis and recurrence risk.

Dante Genomics offers new Rare Disease Health Package to help bring diagnoses to the millions of people living with rare diseases and ending what can be years-long diagnostic odysseys

Retrieved on: 
Monday, June 5, 2023
Genomics, Prognosis, Privacy, Whole genome sequencing, Genetic counseling, Patient, HIPAA, Medicine, WGS, Genetic testing, GDPR, Diagnosis, Rare, Rare disease

NEW YORK, June 5, 2023 /PRNewswire/ -- Dante Genomics, a global leader in genomics and precision medicine, today announced the launch of its Rare Disease Health Package to revolutionize rare disease diagnosis with whole genome sequencing testing.

Key Points: 
  • NEW YORK, June 5, 2023 /PRNewswire/ -- Dante Genomics , a global leader in genomics and precision medicine, today announced the launch of its Rare Disease Health Package to revolutionize rare disease diagnosis with whole genome sequencing testing.
  • The Rare Disease Health Package includes pre- and post-telemedicine consultations with specialist doctors, providing access to specialists who may not be available in a patient's area.
  • Dante removes financial barriers to care by identifying potential treatments and management strategies for rare diseases.
  • With rare diseases in particular, early diagnosis is crucial for optimal treatment, care and genetic counseling regarding prognosis and recurrence risk.

DNAvisit Crosses 2-Year Mark Using Health Gorilla to Access Comprehensive Health Information for Genetic Counseling

Retrieved on: 
Tuesday, May 30, 2023
Genetics, Electronic health record, Genetic counseling, Public Health Information Network, Patient, EHR, Providence Health & Services, MD, Genetic, Weill Cornell Medicine, Roger Hawkins (drummer), Pharmaceutical industry

Mountain View, CA, May 30, 2023 (GLOBE NEWSWIRE) -- Health Gorilla , a leading Health Information Network and interoperability provider, announced that DNAvisit , a technology-powered genetic counseling service, has crossed its two-year anniversary using Health Gorilla’s real-time EHR data retrieval product.

Key Points: 
  • Mountain View, CA, May 30, 2023 (GLOBE NEWSWIRE) -- Health Gorilla , a leading Health Information Network and interoperability provider, announced that DNAvisit , a technology-powered genetic counseling service, has crossed its two-year anniversary using Health Gorilla’s real-time EHR data retrieval product.
  • Through Health Gorilla’s network, DNAvisit has demonstrated substantial progress in exchanging health information, including:
    DNAvisit ( dnavisit.com ) provides genetic counseling services for clinical labs, health plans, and health systems including Weill Cornell Medicine and Providence Health.
  • “We’re thrilled to see DNAvisit cross their two-year anniversary using Health Gorilla to retrieve patient information,” said Steve Yaskin, CEO & Co-founder of Health Gorilla.
  • “With fully informed genetic counselors, DNAvisit has successfully provided genetic counseling services to tens of thousands of patients across the country.

New Research Insights to be Presented by Invitae at the 2023 ASCO Annual Meeting Reinforce the Critical Role of Germline Genetic Testing in Oncology

Retrieved on: 
Friday, May 26, 2023
University of Vermont Medical Center, Pancreatic cancer, Male, University, Stanford University, Registry, GGT, Lung cancer, Genetic testing, Research, Prostate, ASCO, VCU, Genetic counseling, PGV, American Society of Clinical Oncology, Patient, Laboratory, VCU Massey Cancer Center, Colorectal cancer, SAN, Virginia Commonwealth University, Annual general meeting, SEER, CDT, Ovarian cancer, Society, NYSE, Disease, Breast cancer, Prostate cancer, Pharmaceutical industry, Medical device, Vaccine, Medical imaging, Invitae

SAN FRANCISCO, May 26, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced nine studies to be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago from June 2-6, 2023. The new research insights highlight innovations in genetic testing in a variety of clinical settings, population groups and cancer types, and reinforce the need to reduce barriers to genetic services to help patients receive the most effective care and monitoring. 

Key Points: 
  • "Significant gaps persist in the uptake of germline genetic testing across cancer types," stated W. Michael Korn, M.D., chief medical officer for oncology at Invitae.
  • Poster 240/Abstract 10607: Titled: Using patient-reported outcomes to assess the impact of germline genetic testing on prostate cancer patients.
  • Poster 183/Abstract 10550: Titled: Disparities in Germline Genetic Testing Results from a Cohort of ~493,515 Black and White Patients.
  • Poster 250/Abstract 10617: Titled: Eliminating barriers to uptake of germline genetic testing for patients with advanced cancer: the GTAC study.

Genome Medical Supporting Beam Therapeutics on its Sickle Cell Disease Clinical Trial

Retrieved on: 
Thursday, May 25, 2023
Oxygen, Infection, SCD, Clinical trial, Research, Cell, DSM-IV codes, Pain, Genetic counseling, S, Sickle, Fetal hemoglobin, Patient, SAN, Blood, Anemia, Sickle cell disease, Death, Disease, Pharmaceutical industry, Medical imaging, Vaccine, Beam

SOUTH SAN FRANCISCO, Calif., May 25, 2023 /PRNewswire/ -- Genome Medical , the leading telehealth provider of genetic services and solutions, is teaming up with Beam Therapeutics Inc. to provide access to genetic counseling for participants in Beam's BEACON clinical trial evaluating BEAM-101 as a potential treatment for sickle cell disease (SCD).

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 25, 2023 /PRNewswire/ -- Genome Medical , the leading telehealth provider of genetic services and solutions, is teaming up with Beam Therapeutics Inc. to provide access to genetic counseling for participants in Beam's BEACON clinical trial evaluating BEAM-101 as a potential treatment for sickle cell disease (SCD).
  • Through Genome Medical, Beam is sponsoring genetic counseling to provide educational resources and support to its BEACON clinical trial participants as they navigate the complexities that arise from their sickle cell diagnosis and clinical trial journey.
  • Beam will not receive any identifiable information about the patients who elect to pursue genetic counseling with Genome Medical.
  • Sickle cell disease is a group of genetic disorders that affects hemoglobin, the molecule in red blood cells that delivers oxygen to cells throughout the body.

MCI USA Creative Services Team Nominated for 5 EXCEL Awards

Retrieved on: 
Monday, May 22, 2023
Digital design, Communication, Marketing, Genetic counseling, Creative services, Silver, Software and Information Industry Association, Software, MCI, Creativity, International Design Excellence Awards, Gold, Publishing, Editorial, International Society, Catalog, Accreditation, SIIA, Digital, National Association, Book, Biology, Content

WASHINGTON, May 22, 2023 /PRNewswire-PRWeb/ -- MCI USA is proud to announce its print and digital design work has been selected by the Software & Information Industry Association (SIIA) as finalists for five 2023 EXCEL Awards. The US Creative Services department of MCI, a global marketing and engagement agency, was recognized for design work supporting a diverse roster of client partners.

Key Points: 
  • The US Creative Services department of MCI, a global marketing and engagement agency, was recognized for design work supporting a diverse roster of client partners.
  • WASHINGTON, May 22, 2023 /PRNewswire-PRWeb/ -- MCI USA is proud to announce its print and digital design work has been selected by the Software & Information Industry Association (SIIA) as finalists for five 2023 EXCEL Awards.
  • The US Creative Services department of MCI, a global marketing and engagement agency, was recognized for design work supporting a diverse roster of client partners.
  • "Congratulations to MCI USA's Creative Services department for being recognized by SIIA for outstanding work in five categories," said Carrie Hartin, President, Association Solutions, MCI USA.

Learn-Look-Locate Strengthens Growing Panel of Advisors With Influential Trailblazers in Cancer Research, Genetic Testing, Artificial Intelligence, and Restorative Tattooing: Dr. Maryam Lustberg, Lauren Giannetti Sferrazza, Stacey Stevens, and Marnie Rust

Retrieved on: 
Thursday, May 18, 2023
Survivor, Partnership, Education, Friends, Myriad Genetics, Genetic counseling, Heredity, Breast, AAM, Cancer, Yale Cancer Center, Risk assessment, Woman, Wall Street, Associate, LLL, Yale School of Medicine, Genetics, Estate (law), Patient, Breast cancer, Breast disease, Chief Medical Advisor to the President, Internal medicine, Yale University, Diagnosis, CPCP, MPH, Mammography, News, Thyroid cancer, Disease, Medical imaging, MD

Founded by breast cancer survivor, Cynthia Jordan, LLL represents a modern kind of global education hub for breast cancer support.

Key Points: 
  • Founded by breast cancer survivor, Cynthia Jordan, LLL represents a modern kind of global education hub for breast cancer support.
  • Dr. Lustberg is an acclaimed physician and researcher with an extensive background in all-phase clinical trials and breast cancer translational research.
  • Lauren Giannetti Sferrazza, MS CGC, is a certified genetic counselor who currently practices as a National Medical Science Liaison in Oncology at Myriad Genetics.
  • And in addition, LLL and Dr. Charles Weaver already release a monthly Breast Cancer Newsletter that offers support from diagnosis through treatment, and into survivorship.

New Study Shows CancerIQ Plus Point-of-Care Genetic Testing Improves Access to Precision Prevention

Retrieved on: 
Tuesday, May 16, 2023
Oncology, Health, Technology, Hospitals, Genetics, Managed Care, Software, University, Associate professor, Genetics in Medicine, Risk assessment, University of Washington School of Public Health, Cancer, Doctor of Philosophy, Boston University School of Public Health, Genetic counseling, Public health, Patient, Genetic testing, Research, Conference, Vaccine, Nursing, Pharmaceutical industry, Medicine

National efforts have called for increased access to genetic counseling and testing for hereditary cancers among at-risk individuals.

Key Points: 
  • National efforts have called for increased access to genetic counseling and testing for hereditary cancers among at-risk individuals.
  • Research shows the average uptake of genetic counseling after referral is often 16% or lower, reflecting complex barriers to access and clinical workflow challenges.
  • At-risk patients in the study then received follow-up genetic testing through one of four workflows: a traditional referral model, point-of-care scheduling, point-of-care counseling/telegenetics, and point-of-care genetic testing.
  • “Together these strategies can expand access to genetic testing that is essential to improve cancer outcomes at the population level.”
    To meet the growing need for point-of-care genetic resources, CancerIQ recently launched full-service virtual navigation and genetic counseling services: CancerIQ Complete .

Covalon, Leader in Compassionate Pediatric Infection Prevention Solutions, to Participate in Neonatal/Fetal Conference in Columbus, Ohio on May 17 - 19, 2023

Retrieved on: 
Tuesday, May 16, 2023
Other Health, General Health, Oncology, Consumer, Medical Devices, Infectious Diseases, Hospitals, Children, Baby, Maternity, Biotechnology, Medical Supplies, Health, Online, Senior, Pediatrics, Health care, Infection, OH, Uterus, COV, Multimedia, Marketing, Genetic counseling, Student, Patient, Obstetrics, Infant, The Company, Cardiology, Fluid mechanics, FDA, Safety, Nationwide, Conference, Skin, Caregiver, Neonatology, Nursing, Medical device

Healthcare providers looking for more compassionate care solutions for pediatric patients should visit Covalon at exhibit 106 to learn more about Covalon’s unique position to provide “apology-free” dressings.

Key Points: 
  • Healthcare providers looking for more compassionate care solutions for pediatric patients should visit Covalon at exhibit 106 to learn more about Covalon’s unique position to provide “apology-free” dressings.
  • IV Clear ® - the world’s only dual-antimicrobial vascular access dressing that offers complete transparency at and around the insertion site for easy daily assessment.
  • Venue: Online and in person at Nationwide Children’s Hospital Conference Center (520 Butterfly Gardens Dr, Columbus, OH, USA).
  • To make an appointment with Covalon’s on-site representatives, please contact Ron Hebert, SVP Marketing, at [email protected].